ArticleRadiology. Imaging cancer2025
Multiparametric Dynamic Contrast Imaging for Voxelwise Quantitative Assessment of Brain Tumors.
Article in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploratory quantitative magnetic resonance imaging characterization of histopathologic subtype heterogeneity in osteosarcoma.Polish journal of radiology · 2026Article
- Synergistic Breakthroughs in Quantitative Neuro-oncologic MRI-toward a Stable and Comprehensive Clinical Tool.Radiology. Imaging cancer · 2025Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
Purpose To develop a multiparametric dynamic contrast imaging (mpDYCI) technique that enables simultaneous quantification of brain tissue perfusion, microvasculature permeability, transmembrane water efflux, and susceptibility and can be integrated into the routine brain tumor imaging protocol for voxelwise multifaceted quantitative brain tumor assessment. Materials and Methods In this prospective study conducted from March 2023 to April 2024, the mpDYCI technique was evaluated. The mpDYCI technique builds on an MR Multitasking-based dynamic T1 and T2* mapping method and incorporates several technical optimizations in pulse sequence, image reconstruction, T1/T2* quantification, and quantitative metric estimation to achieve robust whole-brain multiparametric quantification. The intersession repeatability and accuracy of mpDYCI metrics were assessed, using intraclass correlation coefficient (ICC), through digital phantom and in vivo experiments involving healthy individuals and individuals with brain tumors. The feasibility of integrating mpDYCI into the routine brain imaging protocol and its clinical utilities based on complementary information from intrinsically coregistered multiple quantitative metrics were also explored. Results In vivo experiments were performed in six healthy participants (mean age, 33 years; range, 27-48 years; three female) and 55 participants with brain tumors (mean age, 56 years; range, 24-81 years; 36 female). Quantitative metrics derived from mpDYCI demonstrated good to excellent repeatability (ICC ≥ 0.80) and excellent agreement with reference standards (range, 6.86%-15.21% percentage error or ICC ≥ 0.93). Histogram analysis, voxel clustering, and histologic validation confirmed the capability of mpDYCI to capture the intratumoral heterogeneity. Low voxelwise correlations between each pair of mpDYCI metrics (correlation coefficient ≤ 0.33 except for one pair) suggested that each metric provides complementary information. Furthermore, mpDYCI exhibited the potential to help differentiate treatment-related effects from true tumor progression in brain metastases. Conclusion With a single 7.5-minute scan and single-dose contrast media injection, mpDYCI can simultaneously quantify perfusion, permeability, water efflux, and susceptibility, thereby enabling comprehensive voxelwise characterization of brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.